Comparison of vinorelbine plus cisplatin and S-1 plus cisplatin in concurrent chemoradiotherapeutic regimens for unresectable stage III non-small cell lung cancer

Anticancer Research

Volumn 32, Issue 2, 2012, Pages 675-680

  Shukuya, Takehito ^a,b   Takahashi, Toshiaki ^a   Harada, Hideyuki ^a   Akamatsu, Hiroaki ^a   Sakaguchi, Chikara ^a   Imai, Hisao ^a   Ono, Akira ^a   Nakamura, Yukiko ^a   Tsuya, Asuka ^a   Kenmotsu, Hirotsugu ^a   Naito, Tateaki ^a   Murakami, Haruyasu ^a   Endo, Masahiro ^a   Takahashi, Kazuhisa ^b   Yamamoto, Nobuyuki ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

Author keywords

Chemoradiotherapy; Cisplatin; Non small cell lung cancer; S 1; Vinorelbine

Indexed keywords

CISPLATIN; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; NAVELBINE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DRUG DOSE REDUCTION; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPONATREMIA; INFECTION; JAPAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; CISPLATIN; DRUG COMBINATIONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; OXONIC ACID; RETROSPECTIVE STUDIES; SURVIVAL RATE; TEGAFUR; TREATMENT OUTCOME; VINBLASTINE;

EID: 84863149244     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC, Carey RW, Frei EF 3rd and Green MR: A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323: 940-945, 1990. (Pubitemid 20332333)
2. Sause W, Kolesar P, Taylor SIV, Johnson D, Livingston R, Komaki R, Emami B, Curran W Jr., Byhardt R, Dar AR and Turrisi A 3rd: Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117: 358-364, 2000. (Pubitemid 30111583)
3. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17: 2692-2699, 1999. (Pubitemid 29415225)
4. Curran WJ Jr., Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Rosenthal SA, Gore E, Machtay M, Sause W and Cox JD: Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 103: 1452-1460, 2011.
5. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J and Johnson DH; Eastern Cooperative Oncology Group: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98, 2002. (Pubitemid 34438899)
6. Bunn PA Jr. and Kelly K: New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions. Clin Cancer Res 4: 1087-1100, 1998.
7. Hoffman PC, Mauer AM and Vokes EE: Lung cancer. Lancet 355: 479-485, 2000. (Pubitemid 30085163)
8. Yamamoto N, Nakagawa K, Nishimura Y, Tsujino K, Satouchi M, Kudo S, Hida T, Kawahara M, Takeda K, Katakami N, Sawa T, Yokota S, Seto T, Imamura F, Saka H, Iwamoto Y, Semba H, Chiba Y, Uejima H and Fukuoka M: Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol 28: 3739-3745, 2010.
9. Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, Radosavljevic D, Paccagnella A, Zatloukal P, Mazzanti P, Bisset D and Rosell R; CISCA (CISplatin versus CArboplatin) Meta-analysis Group: Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 99: 847-857, 2007.
10. Ohyanagi F, Yamamoto N, Horiike A, Harada H, Kozuka T, Murakami H, Gomi K, Takahashi T, Morota M, Nishimura T, Endo M, Nakamura Y, Tsuya A, Horai T and Nishio M: Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. Br J Cancer 101: 225-231, 2009.
11. Sekine I, Noda K, Oshita F, Yamada K, Tanaka M, Yamashita K, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T, Kodama T, Sumi M and Saijo N: Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer. Cancer Sci 95: 691-695, 2004. (Pubitemid 39255819)
12. Mountain CF: Revisions in the Internationl System for Lung Cancer. Chest 111: 1710-1717, 1997.
13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors (RECIST Guidelines). J Natl Cancer Inst 92: 205-216, 2000. (Pubitemid 30099779)
14. National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE) v3.0. http://ctep.cancer.gov/protocolDevelopment/electronic- applications/ctc.htm.
15. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology. Non-small-cell Lung Cancer. http://www.nccn.org/index.asp.